Syndax Pharmaceuticals
SNDX
17.03
-0.34
-1.96%
Syndax Pharmaceuticals
US · SNDX
#2947 by market cap
Listed 2016
17.03
-0.34
-1.96%
Live - 5344 symbols - heartbeat 94s ago
· 2026-10-08 07:42
Pre-market
16.80
-1.35%
After-hours
17.20
+1.00%
- Market cap
- 1.52B
- P/E (TTM)i
- -6.78
- P/Bi
- 100.77
- EPSi
- -3.29
- Div yieldi
- 0.00%
- 52W posi
- 32%
Reader sentiment
Are you bullish or bearish on SNDX?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 3 in the most recent period (2026/Q3).
- Total institutional ownership fell 0.6 percentage points.
Institutional ownership
- Held by institutions
- 122.81% -0.58pp
- Institutions
- 297 -3
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund59.69%
Hedge Fund43.07%
Public Company10.26%
VC/PE Fund6.22%
Private Company2.08%
Individual/Insider1.07%
Insurance Company0.58%
Government Pension Fund0.58%
Family Office/Trust0.33%
Top holders as of 2026-06-30
BlackRock
10.10% · 9.02M sh
Kynam Capital Management, LP
9.02% · 8.05M sh
State Street Global Advisors
6.34% · 5.66M sh
The Goldman Sachs Group, Inc.
6.09% · 5.44M sh
Vanguard Capital Management, LLC
5.11% · 4.56M sh
Deerfield Management Company, L.P.
4.23% · 3.78M sh
Eversept Partners, L.P.
3.13% · 2.80M sh
Bank of America Corporation
2.94% · 2.62M sh
Geode Capital Management, LLC
2.89% · 2.58M sh
Hood River Capital Management LLC
2.87% · 2.56M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 26 buys · 22 sells
| Name | Role | Stake |
|---|---|---|
| Dennis Podlesak | Independent Chairperson | 0.20% |
| Jennifer Jarrett | Independent Director | 0.10% |
| Pierre Legault | Independent Director | 0.10% |
| Keith Katkin | Independent Director | 0.10% |
| Martin Huber | Independent Director | 0.08% |
| Michael Metzger | Chief Executive Officer | 0.07% |
| Nicholas Botwood | Head of Research & Development and Chief Medical Officer | 0.07% |
| Keith Goldan | CFO, Treasurer & Chief Accounting Officer | 0.03% |
| Aleksandra Rizo | Director | 0.03% |
| Neil Gallagher | President of Research & Development | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-07-07 | Michael Metzger | Chief Executive Officer | Derivative Exercise and Sale | -32,375 | $6.38–24.24 |
| 2026-06-11 | Nicholas Botwood | Head of Research & Development and Chief Medical Officer | Derivative Exercise and Sale | -53,750 | $13.82–18.14 |
| 2026-06-11 | Nicholas Botwood | Head of Research & Development and Chief Medical Officer | Intent to Sell (Form 144) | -31,235 | $18.14 |
| 2026-06-10 | Nicholas Botwood | Head of Research & Development and Chief Medical Officer | Automatic Disposition | -11,765 | $18.00 |
| 2026-05-31 | Keith Goldan | CFO, Treasurer & Chief Accounting Officer | Open Market Disposition | -1,177 | $18.99 |
| 2026-05-31 | Michael Metzger | Chief Executive Officer | Open Market Disposition | -6,847 | $18.99 |
| 2026-02-08 | Keith Goldan | CFO, Treasurer & Chief Accounting Officer | Open Market Disposition | -3,410 | $21.03 |
| 2026-02-08 | Michael Metzger | Chief Executive Officer | Open Market Disposition | -17,159 | $21.03 |
| 2026-02-05 | Keith Goldan | CFO, Treasurer & Chief Accounting Officer | Open Market Disposition | -2,082 | $20.62 |
| 2026-02-05 | Michael Metzger | Chief Executive Officer | Open Market Disposition | -7,412 | $20.62 |
| 2026-02-03 | Keith Katkin | Independent Director | Other Acquisition | +24,000 | -- |
| 2026-02-03 | Pierre Legault | Independent Director | Other Acquisition | +24,000 | -- |
| 2026-02-03 | Keith Goldan | CFO, Treasurer & Chief Accounting Officer | Other Acquisition | +52,250 | -- |
| 2026-02-03 | Keith Goldan | CFO, Treasurer & Chief Accounting Officer | Other Derivative Acquisition | +118,000 | $20.43 |
| 2026-02-03 | Dennis Podlesak | Independent Chairperson | Other Acquisition | +48,000 | -- |
| 2026-02-03 | Michael Metzger | Chief Executive Officer | Other Acquisition | +217,600 | -- |
| 2026-02-03 | Michael Metzger | Chief Executive Officer | Other Derivative Acquisition | +440,000 | $20.43 |
| 2026-02-03 | Jennifer Jarrett | Independent Director | Other Acquisition | +24,000 | -- |
| 2026-02-03 | Aleksandra Rizo | Director | Other Acquisition | +24,000 | -- |
| 2026-02-03 | Martin Huber | Independent Director | Other Acquisition | +24,000 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 07:42:13 · For reference only, not investment advice and not tailored to your situation.